SCHEMBL541315

SCHEMBL541315

C=CCC=C(C#N)C(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.56
MAPT P10636 7/20 0.52
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPSR1 Q6W5P4 4/20 0.52
KDM4E B2RXH2 3/20 0.52
USP2 O75604 3/20 0.52
GAA P10253 3/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 2/20 0.52
TP53 P04637 1/20 0.52
THRB P10828 1/20 0.52
HPGD P15428 1/20 0.52
MCOLN3 Q8TDD5 1/20 0.52
ALDH1A1 P00352 7/20 0.50
TSHR P16473 1/20 0.50
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074959 0.84 TP53 (0.46) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL27410309 0.82 ADORA2A (0.40) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL11269373 0.82 CYP2C9 (0.62) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL167038 0.82 CYP2C9 (0.62) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL4906704 0.79 CYP2C9 (0.69) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL4961560 0.79 CYP2C9 (0.69) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL2755215 0.79 CYP2C9 (0.69) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL7901288 0.79 CYP2C9 (0.59) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL7901285 0.79 CYP2C9 (0.59) CYP2C9MAPTMEN1KMT2ARAB9A
SCHEMBL8569025 0.79 CYP2C9 (0.59) CYP2C9MAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089308-B1 DISPENSER ETHICON INC (US) 2018-12-26 EP disclosed
US-8287202-B2 Method for dispensing a polymerizable monomer adhesive ETHICON, INC. (US) 2012-10-16 US disclosed
US-20120160867-A1 DISPENSER WITH A FRANGIBLE CONTAINER AND A ROTATING BREAKING MEMBER, FOR DISPENSING A POLYMERIZABLE MONOMER ADHESIVE CLOSURE MEDICAL CORPORATION 2012-06-28 US disclosed
US-8118508-B2 Dispenser with a frangible container and a rotating breaking member, for dispensing a polymerizable monomer adhesive CLOSURE MEDICAL CORPORATION (US) 2012-02-21 US disclosed
EP-2413943-A1 CONTROLLED EXOTHERM OF CYANOACRYLATE FORMULATIONS Ethicon, Inc (US) 2012-02-08 EP disclosed
US-7932305-B2 Viscous α-cyanoacrylate compositions ETHICON, INC. (US) 2011-04-26 US disclosed
US-20100269749-A1 Absorbable Cyanoacrylate Compositions ETHICON, INC. 2010-10-28 US disclosed
WO-2010114779-A1 CONTROLLED EXOTHERM OF CYANOACRYLATE FORMULATIONS ETHICON, INC. (US) 2010-10-07 WO disclosed
US-20100249698-A1 CONTROLLED EXOTHERM OF CYANOACRYLATE FORMULATIONS ETHICON, INC. 2010-09-30 US disclosed
US-20090326095-A1 Viscous alpha-Cyanoacrylate Compositions ETHICON, INC. 2009-12-31 US disclosed
WO-2009158302-A2 VISCOUS ALPHA-CYANOACRYLATE COMPOSITIONS CLOSURE MEDICAL CORPORATION (US) 2009-12-30 WO disclosed
EP-2089308-A2 DISPENSER Closure Medical Corporation (US) 2009-08-19 EP disclosed
US-20080241249-A1 Cyanoacrylate composite CLOSURE MEDICAL CORPORATION (US) 2008-10-02 US disclosed
EP-1928920-A2 IMPROVED STABILIZER CYANOACRYLATE FORMULATIONS Closure Medical Corporation (US) 2008-06-11 EP disclosed
US-20080131190-A1 Dispenser ETHICON, INC. 2008-06-05 US disclosed
WO-2008067220-A2 DISPENSER CLOSURE MEDICAL CORPORATION (US) 2008-06-05 WO disclosed
WO-2008005634-A1 ABSORBABLE CYANOACRYLATE COMPOSITIONS CLOSURE MEDICAL CORPORATION (US) 2008-01-10 WO disclosed
US-20080003196-A1 Absorbable cyanoacrylate compositions ETHICON, INC. 2008-01-03 US disclosed
WO-2007041143-A2 IMPROVED STABILIZER CYANOACRYLATE FORMULATIONS CLOSURE MEDICAL CORPORATION (US) 2007-04-12 WO disclosed
US-20070078207-A1 Stabilizer cyanoacrylate formulations ETHICON, INC. 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241249-A1 Cyanoacrylate composite ALOX5, SCD, SCD5 CYP2C9 3993/4885MAPT 1601/4885MEN1 3034/4885
US-20080003196-A1 Absorbable cyanoacrylate compositions PCNA, FGB, F13A1 CYP2C9 3854/4885MAPT 2245/4885MEN1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.